2024 ACCP Virtual Journal Club Webinar: Edoxaban Exposure in Patients with Atrial Fibrillation and Estimated Creatinine Clearance Exceeding 100 mL/min - On Demand

Live Session: Wednesday, March 20^th, 2024, from 2:00 to 3:00 PM ET

On Demand: March 20^th, 2024 to March 20^th, 2027

Why is this article important to your practice? 

There is a lack of clear understanding of high creatinine clearance on pharmacokinetic/pharmacodynamic (PK/PD) outcomes. Edoxaban 60 mg is approved for stroke prevention in patients with atrial fibrillation (AF) not fulfilling any dose-reduction criteria. As edoxaban is partially renally cleared (≈50%), it was postulated that edoxaban exposure may be lower in patients with high creatinine clearance (CrCL >100 mL/min); thus, efficacy could hypothetically be lower in this subpopulation. In this webinar, the author will discuss a prospective, randomized, double-blinded study comparing the pharmacokinetics, pharmacodynamics, efficacy and safety outcomes of edoxaban 60 mg once daily versus edoxaban 75 mg once daily in patients with CrCL exceeding 100 mL/min. The presentation will also illustrate the utility of population PK modeling to account for variability and estimate steady-state PK values based on the sparse PK concentrations collected in the study. 

Target Audience:

Interprofessional team of Physicians, Pharmacists, PhDs, and other health care professionals.

Learning Objectives

After completing this activity, the learner will be able to:

• Describe the impact of high creatinine clearance on edoxaban PK and PD and the potential clinical implications;
• Recognize the utility of population PK modeling in analyzing sparse PK concentrations collected from clinical studies;
• Describe the key elements of a prospective, randomized, placebo-controlled clinical trial.